PDCD1 and metastatic melanoma: Two phase 1 trials were recently published in Science investigating FMT from immunotherapy responders combined with anti-PD-1 antibodies as a strategy to overcome anti-PD-1 resistance in patients with metastatic melanoma [42,44].